# Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

> **NCT00914940** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 41 (actual)

## Conditions studied

- Graft Versus Host Disease
- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Fludarabine Phosphate
- **DRUG:** Tacrolimus
- **DRUG:** Thiotepa
- **RADIATION:** Total-Body Irradiation (TBI)
- **OTHER:** Magnetic Affinity Cell Sorting
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **BIOLOGICAL:** T Cell-Depleted Hematopoietic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT00914940
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12-17
- **Primary completion:** 2019-12-01
- **Final completion:** 2020-05-26
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Did not reach one of the primary endpoints of decreased total acute GVHD
- **Last updated:** 2020-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914940, "Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00914940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*